AbbVie closes $200M Nimble Therapeutics acquisition
AbbVie closes $200M Nimble Therapeutics acquisition
STARTS NOW! Rebel Edge 🏴☠️1pm line up: U.S. crude oil prices are dropping due to weak demand from China and expected higher U.S. production after the election. WTI is notably lower, part of a wider commodity slump. Stocks $TSLA $COIN $ABBV $HOOD Sports Detroit's kicker makes 58… https://t.co/mZXNAn84q8 https://t.co/HBCDrov0gz
Bristol Myers Squibb’s stock soars after rival AbbVie reports disappointing schizophrenia-drug trial
M&A deals roundup: AbbVie, Blackstone, Take-Two Interactive and more
AbbVie to buy Aliada Therapeutics for $1.4B in cash
AbbVie wins FDA nod for infusion treatment for advanced Parkinson’s disease
374.36BUSD
See which Billionaires own this investment
Type
Common Stock
Exchange
NYSE
Currency Code
USD
Currency Name
US Dollar
Country Name
USA
Country ISO
US
ISIN
US00287Y1091
CUSIP
00287Y109
Sector
Healthcare
Industry
Drug Manufacturers - General
Fiscal Year End
December
IPO date
-
Updated At
-
PE Ratio
88.51
PEG Ratio
0.44
Book Value
1.88
Dividend Share
6.29
Dividend Yield
3.09%
Earnings Share
2.39
Wall Street Target Price
211.05
EPS Estimate Current Year
12.28
EPS Estimate Next Year
13.88
EPS Estimate Current Quarter
2.258
EPS Estimate Next Quarter
2.5852
Most Recent Quarter
-
Revenue TTM
56,334,000,128
Gross Profit TTM
39,608,999,936
EBITDA
26,208,000,000
Profit Margin
7.59%
Return On Assets TTM
8.26%
Return On Equity TTM
62.29%
Revenue Per Share TTM
31.845
Qtly Revenue Growth YOY
5.60%
Diluted Eps TTM
2.39
Qtly Earnings Growth YOY
-12.30%
Trailing PE
88.51
Forward PE
17
Price Sales TTM
6.6294
Price Book MRQ
112.319
Enterprise Value Revenue
7
Enterprise Value EBITDA
29
154.46
3.39%77.20
1.85%812.00
1.51%77.04
0.67%109.00
0.00%341.79
-1.50%42.97
-1.35%162.22
-0.48%375.00
-0.27%94.64
-0.07%Curated watchlists where ABBV is featured.